🔥🚨@OncoAlert Hot off the press.

Just published @NEJM in conjunction with presentation @myESMO #ESMO26 results of:

⭐️#SAFFRON phase 3 trial of:

❇️#Osimertinib + #Savolitinib (#MET #TKI)!
Vs
#Chemotherapy (platinum/pemetrexed)

🎯For #2ndLine Tx of #EGFR+ advanced non-small-cell #LungCancer (#NSCLC) with:
🔹#MET #Overexpression or #Amplification or both
🔹#Progression on #Osimertinib

Study showed:

‼️Statistically significant & clinically meaningful ⬆️#ProgressionFreeSurvival (primary endpoint) & #OverallSurvival Benefits.

✅#mPFS: 7.6 vs 5.4 months (HR 0.55)
✅#mOS: 17.8 vs 12.9 months (HR 0.68)
✅ ⚠️ Grade ≥3 AEs: 64% vs 63%

👇🏻
https://www.nejm.org/doi/full/10.1056/NEJMoa2611335?query=featured_home